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Thrombospondin-1 is a major activator of TGF-b in fibrotic
renal disease in the rat in vivo.
Background. Transforming growth factor-b (TGF-b), a profi-
brotic cytokine involved in many scarring processes, has to
be activated extracellularly before it can bind to its receptors.
Thrombospondin 1 (TSP1), a multifunctional matricellular gly-
coprotein, has been identified as an activator of TGF-b in in
vitro systems and during mouse postnatal development in vivo.
TSP1 is expressed de novo in many inflammatory disease pro-
cesses, including glomerular disease.
Methods. In this study we investigated whether peptides
specifically interfering with the activation process of TGF-b by
TSP1 may be able to block activation of TGF-b in an in vivo
model of mesangial proliferative glomerulonephritis.
Results. Continuous intravenous infusion of blocking peptide
by minipumps significantly reduced expression of active TGF-b
in glomeruli on day 7 of disease as indicated by immunohisto-
chemistry, bioassay, and activation of the TGF-b signal trans-
duction pathway, while total TGF-b expression was unchanged.
Inhibition of glomerular TGF-b activation was accompanied by
a decrease of glomerular extracellular matrix accumulation and
proteinuria, but was without effect on mesangial cell prolifera-
tion or influx of monocytes/macrophages.
Conclusion. TSP1 is a major endogenous activator of TGF-b
in experimental inflammatory glomerular disease. Drugs inter-
fering with the activation of TGF-b by locally produced TSP1
may be considered as a future specific treatment of scarring
kidney disease.
Extracellular matrix accumulation is one of the hall-
marks of inflammatory diseases in many organ systems,
including the kidney, and is the major cause of end-
stage renal disease in humans. Mesangial proliferative
glomerulonephritis, the most common type of glomeru-
lonephritis in the Western world [1], is characterized by
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mesangial cell (MC) proliferation and extracellular ma-
trix expansion [2]. In up to 50% of the patients with
mesangial proliferative glomerulonephritis, the disease
process eventually progresses to end-stage renal disease
because specific treatment is still lacking [3]. Typical fea-
tures of human mesangial proliferative glomerulonephri-
tis are mimicked by an experimental model in the rat,
induced by an antibody against the Thy1-antigen on MC
[2].
The role of transforming growth factor-b (TGF-b) as
a major profibrotic cytokine in the anti-Thy1 model has
been well established [4]. It has been demonstrated that
TGF-b1 mRNA and protein are increased in the anti-
Thy1 model [5], and that blocking TGF-b1 by injections
with a polyclonal anti-TGF-b1 antibody or the proteo-
glycan decorin, a TGF-b1, -2, and -3 binding protein [7],
markedly reduced extracellular matrix accumulation [6].
The results of these studies were confirmed by studies us-
ing equivalent gene transfer techniques against TGF-b in
the anti-Thy1 model [8, 9]. In contrast, mice transgenic for
an active form of TGF-b1 exhibit elevated plasma levels
of TGF-b1 and develop progressive renal disease charac-
terized by MC matrix accumulation, interstitial fibrosis,
and proteinuria [10]. Transfer of the TGF-b1 gene into
glomeruli of normal rats caused an increase in glomerular
TGF-b1 protein that was linked to extracellular matrix
formation [11]. The potential importance of TGF-b in
mediating fibrosis also in human kidney disease has been
supported by the widespread link of TGF-b up-regulation
and extracellular matrix excess in many different types
of human kidney disease [4]. While these studies suggest
great benefit from suppression of TGF-b function in fi-
brotic kidney disease, it has to be considered that TGF-b
is a multifunctional cytokine that exhibits other essential
functions in mammals. Mice lacking either the TGF-b1,
-2, or -3 gene do not survive beyond a few weeks after
birth [12–14]. Therefore, accurate regulation of TGF-b
function seems to be critical for the health of mammals
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and any anti-TGFb1 therapeutic approach should try to
target the local overproduction (-function) of TGF-b as
specifically as possible.
One possiblilty to approach this goal could be to con-
trol the activation process of locally produced TGF-b .
TGF-b is secreted by most cell types as a latent, inactive
procytokine complex [15]. The mature TGF-b protein has
to be extracellularly released from this procytokine com-
plex to be able to interact with its receptors. While various
players/mechanisms such as pH changes, gamma irradia-
tion, reactive oxygen species, plasmin, calpain, cathepsin,
or TSP1 have been identified as activating TGF-b under
in vitro conditions, it is still unknown how TGF-b is acti-
vated in an inflammatory process in vivo [15].
Recent data have suggested the homeotrimeric extra-
cellular matrix protein TSP1 as an activator of TGF-b1
in vitro in different cell systems including MC [16–18], as
well as in cell-free systems. It has been demonstrated that
TSP1 forms a trimolecular complex with the TGF-b pro-
cytokine complex by interacting with the mature TGF-b
protein as well as the so-called latency-associated pep-
tide (LAP). Hereby, the hexapeptide AAWSHW from
the type I repeat of the TSP1 molecule is required for
TSP1 binding to the mature TGF-b protein, allowing in-
teraction of the KRFK amino acid sequence of the TSP1
molecule with the N-terminal LSKL sequence of the LAP
[19, 20]. This complex interaction leads to a confirma-
tional change, probably within the LAP, that allows the
mature TGF-b protein to bind to its receptors. It has
been shown that both the hexapeptide AAWSHW and
the LSKL peptide are able to block activation of TGF-
b by TSP1. In addition, comparing TSP1 null mice with
TGF-b1 null mice, Crawford et al [21] identified TSP1 as
a major activator of TGF-b1 in pancreas and lung home-
ostasis in mice pups in vivo. Organ pathology of TGF-b1
null pups and TSP1 null pups were strikingly similar and
could be induced in wild-type pups by intraperitoneal
treatment with the LSKL peptide that specifically blocks
activation of TGF-b1 by TSP1. Loss of TSP1 expression
in TSP1-null mice spontaneously produced inflammatory
lung disease [22], and histologic changes in TSP1 null mice
reverted toward wild-type by treatment with the TGF-b
activating peptide KRFK.
Interestingly, TSP1 expression in vitro is regulated by
various cytokines such as platelet-derived growth factor
(PDGF), fibroblast growth factor-2 (FGF-2), or TGFb ,
and is frequently expressed de novo at sites of inflamma-
tion and wound healing [23]. The involvement of TSP1
in the anti-Thy1 model has been currently demonstrated
[24].
Therefore, we hypothesized that TSP1 is an endoge-
nous activator of TGF-b in inflammatory kidney disease
and investigated whether systemic treatment with either
one of two blocking peptides that interfere with TSP1-
TGF-b1 binding (LSKL or AAWSHW) is able to sup-
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Fig. 1. Shown is the schematic outline of the experimental design.
press activation and thereby function of TGF-b in exper-
imental mesangial proliferative nephritis in the rat.
METHODS
Experimental design
A scheme of the experimental protocol is shown in
Figure 1. An identical pilot study in four to six rats per
group using half of the peptide dose was done without
glomerular preparations. Experimental mesangial prolif-
erative glomerulonephritis was induced using the mon-
oclonal mouse anti-Thy1 antibody OX-7. Peptides were
continuously infused intravenously via jugular vein using
osmotic minipumps starting 16 hours after disease induc-
tion. The effects of the hexapeptide AAWSHW (which
interfere with the TSP1-mature TGF-b interaction) or
the LSKL peptide (that blocks the TSP1-LAP interac-
tion) were compared with a control peptide (SLLK) in
the anti-Thy1 model. Tissues from different time points
(days 3, 5, 7) of this experiment were analyzed in regard
to mesangiolysis, macrophage influx, MC proliferation,
microaneurysm, and matrix formation, GEN prolifera-
tion, TSP1, active TGF-b , total TGF-b1 and -2, as well
as TGF-bRI and RII, and phosphorylation of the TGF-b
signaling molecule Smad2/3. Functional parameters such
as blood pressure, proteinuria, and creatinine clearance
were also determined. On day 7, glomerular secretion of
active TGF-b was determined in individual animals using
the NRK bioassay.
Animal model
Experimental mesangial proliferative glomeru-
lonephritis (anti-Thy1 model) was induced in Sprague
Dawley rats (180–200 g; Charles River, Sulzfeld,
Germany) by a single injection of 1 mg/kg of the
mouse monoclonal anti-Thy1 antibody OX-7 (European
Collection of Animal Cell Culture, Salisbury, UK). In
this animal model, complete anti-Thy1 antibody binding
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occurs within an hour [26]. To avoid potential inter-
ference of the TSP-peptides with anti-Thy1 antibody
binding and subsequent mesangiolysis, the peptide treat-
ment was started 16 hours after disease induction, when
binding of the anti-Thy1 antibody to the mesangium and
subsequent mesangiolysis had already occurred. The
peptides used in this study were synthesized, purified,
and analyzed as described elsewhere [27].
As shown in Figure 1, six rats per group received treat-
ment either with a control peptide SLLK-group 1, or
with the LAP peptide LSKL-group 2, or with the TSP
hexapeptide AAWSHW-group 3. Renal biopsies as de-
scribed previously [28] were performed on days 3 and
5, and the experiment was finished on day 7. To deter-
mine DNA incorporation into proliferating cells, each
animal was injected intravenously with BrdU (50 mg/kg
bw) 90 minutes before the second survival biopsy was
taken on day 5 (peak of MC proliferation). A 24-hour
urine collection for measurement of protein and creati-
nine was done from day 6 to 7, when maximal protein-
uria occurs in this model. Blood pressure measurements
were done twice before and twice after disease induction.
For TGF-b activity measurements in individual animals
on day 7, glomeruli were isolated by differential sieving
[26] and counted using 5 aliquots. Glomerular isolates
were discarded if purity was less than 95%. Glomeruli
(8000 mL) were incubated in Dulbecco’s modified Ea-
gle’s medium (DMEM) at 37◦C. After a 24-hour incu-
bation period, glomerular supernatants were stored by
−70◦C until TGF-b activity measurements were done.
Peptide infusion
All peptides (at a concentration of 7 mg/mL) were con-
tinuously infused for 7 days via a catheter in the right jugu-
lar vein using osmotic minipumps (Alzet Corp., Charles
River, Sulzfeld, Germany). Implantation of minipumps
(filling volume: 2 mL, delivery rate: 10 lL/h) and catheter
was started 16 hours after disease induction and was im-
mediately followed by an additional intravenous injection
of 6 mg peptide per kg body weight before rats recovered
from anesthesia. Effective peptide doses were extrapo-
lated from previous pilot studies with TSP peptides as
described elsewhere [29], from an additional pilot exper-
iment using these peptides, and from the literature [21,
30]. Because using a peptide concentration of 3.5 mg/mL
in this pilot experiment already profound effects on ma-
trix formation and no toxicity were noted, in the final
study described in the current paper the peptide dose
again doubled compared to the pilot study. The final pep-
tide dose per animal/week in this study (as stated above)
is in the same range as used in mice by Crawford et al
[21], where the identical peptides were successfully ap-
plied intraperitoneally on a daily basis. Considering the
results of a study [30] regarding the biodistribution and
blood half-life of TSP peptides, a continuous intravenous
application of peptides was chosen.
Renal morphology and immunohistochemistry
Renal biopsies were fixed in methyl Carnoy’s solution,
embedded in paraffin, and cut into 5-lm sections for indi-
rect immunoperoxidase staining as described elsewhere
[26]. Sections were also stained with the periodic-acid
Schiff reagent and counterstained with hematoxylin. For
each biopsy, 40 to 70 cortical glomerular cross-sections
were evaluated in a blinded fashion, each containing
more than 20 discrete capillary segments.
Mesangiolysis was graded semiquantitatively using the
following scale: 0 = no mesangiolysis; I = segmental and
focal mesangiolysis (less than 25% of the glomeruli show
partial dissolution of the mesangium); II = 25%–50%
of the glomeruli are affected; III = most (50%–75%)
glomeruli show severe mesangiolysis; and IV = global
mesangiolysis, where virtually all glomeruli show a com-
plete dissolution of the mesangial areas. To determine
general extracellular matrix formation, sections were also
stained with the Masson’s Trichrome (blue color) and
semiquantitatively scored from 0 to 3 as follows: score 0 =
glomerulus without any blue staining; score 1 = glomeru-
lus with little blue staining; score 2 = glomerulus with
moderate blue staining; and score 3 = glomerulus almost
completely filled with blue staining.
The following antibodies were used in this study: a
murine immunoglobulin (Ig)M monoclonal antibody
(mAb) against the proliferating cell nuclear antigen
(PCNA) (19A2; Coulter Immunology, Hialeah, FL,
USA); a murine IgG monoclonal antibody (mAb)
against bromodeoxyuridine (BrdU); (ED-1, a murine
IgG1 mAb to a cytoplasmic antigen present in monocytes,
macrophages, and dendritic cells (Serotec, Ltd., Oxford,
UK); OX-7, a murine IgG1 mAb specific for mesangial
cells (Serotec); Immunostaining for matrix proteins
was conducted with polyclonal antibodies to collagen I,
collagen IV (goat anti-human/bovine collagen IV; South-
ern Biotechnology Associates, Inc., Birmingham, AL,
USA), fibronectin (rabbit anti-rat fibronectin; Chemi-
con International, Inc., Temecula, CA, USA), active
TGF-b1 (chicken anti-human active TGF-b1; R&D Sys-
tems, Wiesbaden-Nordenstadt, Germany [25], TGF-b1
(rabbit anti-human TGF-b1; Santa Cruz Biotechnology,
Inc., Santa Cruz, CA, USA), TGF-b2 (rabbit anti-human
TGF-b2; Santa Cruz), TGF-bR1 (rabbit anti-
human TGF-bR1; Santa Cruz), TGF-bR2 (rabbit
anti-human TGF-bR2; Santa Cruz), Phospho-Smad2/3
(rabbit anti-human Smad2 peptide phosphorylated at
Ser-433/435; Santa Cruz), and a murine IgG1 mAb
against TSP1 (clone A 6.1; Dunn, Labortechnik GmbH,
Asbach, Germany). Negative controls for immunos-
taining included either deleting the primary antibody
or substitution of the primary antibody with equivalent
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concentrations of an irrelevant murine monoclonal
antibody or preimmune rabbit IgG.
Glomerular active TGF-b and expression of matrix
monitored by collagen I, collagen IV, and fibronectin was
quantified by computerized measurement of the positive-
stained glomerular area using the Metavue Imaging Sys-
tem (Visitron Systems GmbH, Puchheim, Germany) and
with equivalent results by a semiquantitative scoring sys-
tem (data not shown) as described below. Total TGF-b1,
total TGF-b2, and TSP1 was graded semiquantitatively
[24] and reflected changes in the area and intensity of
mesangial staining: 0: very weak or absent staining; 1+:
weak staining with <25% of the glomerular tuft showing
focally increased staining; 2+: 25%–49% of the glomeru-
lar tuft with focally increased staining; 3+: 50%–75% of
the glomerular tuft demonstrating increased staining; 4+:
>75% of the glomerular tuft stained strongly. In addition,
the average number of ED-1 or phospho-Smad2/3 posi-
tive cells per glomerular cross-section was determined.
Immunohistochemical double staining
To determine the number of proliferating MC, dou-
ble immunostaining for PCNA or BrdU, both markers
of cell proliferation, and for OX-7, a MC-specific marker
was performed as described previously [24]. The num-
ber of proliferating MC was evaluated by counting the
number of cells that stained for both PCNA (black)
and OX-7 (brown) or BrdU (black) and OX-7 (brown)
as PCNA+/OX-7+ or BrdU+/OX-7+ cells, respectively,
and was expressed as mean ± SD per glomerular cross-
section.
Glomerular TGF-b -activity
Active TGF-b was measured three different ways.
First, using a well-established bioassay system, ac-
tive TGF-b present in glomerular supernatants after a
24-hour incubation period was determined by colony for-
mation by NRK cells in soft agar assays as described pre-
viously [18]. The number of colonies greater than 62 lm
(≥8–10 cells) in diameter was counted. Recombinant ac-
tive TGF-b1 (R&D Systems, Germany) was used as a
control. All experiments were done twice in triplicate.
In addition, activation of TGF-b was evaluated using an
antibody against active TGF-b1 (chicken anti-human ac-
tive TGF-b1, R&D Systems, Germany) [25], and an an-
tibody against the phosphorylated form of the TGF-b
signaling molecule Smad2/3 by counting positive nuclei
per glomerular cross section (Santa Cruz).
Miscellanous measurements
Urinary protein was measured using the BioRad Pro-
tein Assay (Mu¨nchen, Germany) and bovine serum
albumin (BSA) (Sigma, Deisenhofen, Germany) as a
standard. Creatinine in serum or urine, as well as blood
urea nitrogen, were measured using an autoanalyzer
(Beckman Instruments GmbH, Mu¨nchen, Germany).
Systolic blood pressure was measured by tail plethysmog-
raphy in conditioned, conscious rats [31].
Statistical analysis
All values are expressed as mean SD. Statistical sig-
nificance (defined as P < 0.05) was evaluated using the
Student t test or one-way analysis of variance (ANOVA)
with modified t test using the Bonferroni method.
RESULTS
Blocking peptides decreases activation of TGF-b
in glomeruli from rats with anti-Thy1 disease
If the de novo expressed TSP1 is activating TGF-b in
the anti-Thy1 model, TGF-b activity in glomeruli from
blocking peptide treated animals had to be reduced. Since
the amount of active TGF-b1 or TGF-b2 in glomeruli
from individual rats was too small to be detectable by
commercially available TGF-b-Assays (R&D Systems,
or Genzyme, Neu-Isenburg, Germany), TGF-b bioassays
for measuring the active TGF-b fraction were applied.
In the mink lung assay, TSP peptides have been shown
to influence growth of the mink lung cells in a TGF-b–
independent fashion ([27] and this study). Since the NRK
assay has been shown to be sensitive and specific for TGF-
b activity measurements [16, 18–21], this well-established
assay was used to determine glomerular TGF-b activity
of peptide-treated animals. Since detergents used for pro-
tein extraction of glomeruli interfer with the NRK bioas-
say (this study) and may potentially lead to unspecific
activation of TGF-b , isolated glomeruli from day 7 ani-
mals were incubated for a 24-hour period in DMEM at
37◦C, and the amount of secreted active TGF-b by these
glomeruli was determined in the supernatant. As shown
in Figure 2A, glomerular secretion of active TGF-b was
markedly reduced in the LAP peptide (LSKL) treated
group as well as in the TSP1 peptide (AAWSHW) treated
group compared to control peptide (SLLK) treated rats
(P < 0.01).
In addition, active TGF-b in nephritic glomeruli was
determined by immunostaining with an antibody recog-
nizing the active form of TGF-b1 (Fig. 2C). In agree-
ment with the bioassay results, the treatment with the
two blocking peptides, but not with the control peptide,
was associated with a markedly decreased glomerular
TGF-b activity measured by computerized morphome-
try (Fig. 2B).
Binding of active TGF-b to its receptors is followed by
activation of the Smad signaling pathway. Phosphoryla-
tion and transport into the nucleus of Smad2/3 is an im-
portant part of the TGF-b–mediated signaling pathway
and serves as a marker for TGF-b activation [32]. There-
fore, activation of TGF-b was additionally evaluated us-
ing an antibody against the phosphorylated form of the
Smad2/3 molecule and the ratio of positive nuclei per
Daniel et al: Thrombospondin-1 activates TGF-b in renal fibrosis 463
0
100
200
300
400
500
Co
lo
ni
es
 >
62
 µ
m
Control/
SLLK
LSKL AAWSHW
Day  7A
15
10
5
0
G
lo
m
er
ul
ar
 a
ct
ive
 T
G
F-
β,
%
 p
os
itiv
e 
ar
ea
Healthy Day 3 Day 5 Day 7
B
0
5
10
15
20
25
30
35
%
 P
-S
m
ad
 2
/3
 p
os
itiv
e 
nu
cle
i p
er
gl
om
er
ul
ar
 c
ro
ss
-s
ec
tio
n
Day 0 Day 5 Day 7
D
0
0.5
1
1.5
2
2.5
G
lo
m
er
ul
ar
 to
ta
l T
G
F-
β 1
, s
co
re
 0
-4
Day 3 Day 5 Day 7
E
0
0.5
1
1.5
2
G
lo
m
er
ul
ar
 to
ta
l T
G
F-
β 2
, s
co
re
 0
-4
Day 3 Day 5 Day 7
F
C
Fig. 2. Therapy using blocking peptides
(LSKL or AAWSHW) decreased glomerular
activation of TGF-b in rats with anti-Thy1 dis-
ease. TGF-b activation was monitored either
in supernatants from day 7 isolated glomeruli
by using the NRK-bioassay (A), by immunos-
taining of active TGF-b (B, C, gray staining),
or immunostaining of the phosphorylated
TGF-b signaling molecule Smad2/3 in paraf-
fin embedded tissue sections (D). A marked
reduction of the active fraction of glomeru-
lar TGF-b was induced by either blocking
(LSKL, hatched bars, or AAWSHW, black
bars) versus control (SLLK, white bars) pep-
tide and could be demonstrated by all used
methods (A, B, D). In contrast, total TGF-b1
(E) or TGF-b2 (F) as assessed by immunos-
taining was not significantly affected by block-
ing peptid therapy. The asterisk marks signif-
icant differences (P < 0.01) of the blocking
peptide groups versus the control group.
glomerular cross-section was determined. Again, LSKL
more than AAWSHW treatment reduced glomerular
TGF-b activity on days 5 and 7 compared to the SLLK
control as assessed by P-Smad2/3 immunostaining (Fig.
2D). On day 7 of anti-Thy1 disease, blocking peptide
treatment led to a complete reduction of the percentage
of P-Smad2/3–positive glomerular nuclei down to normal
undiseased levels (day 0).
In contrast, total TGF-b1 or TGF-b2 as assessed by im-
munostaining was not significantly affected by blocking
peptide therapy (Fig. 2E and F).
Blocking peptides decreases glomerular extracellular
matrix formation in rats with anti-Thy1 disease
Since TGF-b has been demonstrated to cause excess
formation of extracellular matrix in the anti-Thy1 model
[6–9], we evaluated if suppression of TGF-b activity by
blocking peptides is accompanied by decreased matrix
formation. Using Masson’s Trichrome staining as a gen-
eral indicator for fibrosis (blue color), no blue staining
is detected in normal glomeruli. In the anti-Thy1 model,
diseased glomeruli on day 3 or day 5 exhibit no or very
little blue staining, while a marked increase in blue stain-
ing was seen on day 7 (Fig. 3). Treatment with either the
LAP peptide (LSKL) or the TSP1 peptide (AAWSHW)
markedly suppressed extracellular matrix formation on
day 7 as determined by Trichrome staining (Figs. 3A
and B and 4A). This result was confirmed by examining
specific typical extracellular matrix proteins such as colla-
gen I and IV, as well as fibronectin during the time course
of anti-Thy1 disease using immunohistochemistry. In the
anti-Thy1 model, the typical interstitial protein collagen I
is transiently expressed de novo by glomerular MC start-
ing on day 3 and peaking on day 5, while the constitutively
expressed MC proteins collagen IV and fibronectin are
also markedly increased in parallel to collagen I. Treat-
ment with either the LAP peptide (LSKL) or the TSP1
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Fig. 3. Blocking peptides (LSKL or AAWSHW) decreased glomeru-
lar extracellular matrix formation in rats with anti-Thy1 disease. Using
Masson’s Trichrome staining as a general indicator for fibrosis (as indi-
cated by dark staining) a marked reduction in blue staining was seen in
day 7 glomeruli from the blocking peptide treated groups (B) compared
to the control group (A). In addition, immunostaining for collagen I
(C, D) or collagen IV (E, F) in dark gray was clearly reduced in day 7
glomeruli from the peptide treated animals (D, F) compared to control
animals (C, E).
peptide (AAWSHW) reduced glomerular accumulation
of all three extracellular matrix proteins as determined by
immunohistochemistry (Figs. 3 and 4). Evaluation of ex-
tracellular matrix accumulation using computerized mor-
phometry demonstrated that the changes induced by the
treatment of either the LSKL or the AAWSHW peptide
were significant compared to the control peptide and that
in general the LSKL peptide treatment was slightly su-
perior to the AAWSHW peptide in suppressing matrix
accumulation as well as TGF-b activity (Figs. 3 and 4).
Blocking peptides does not affect the glomerular
amount of TGF-b1 or -b2, TGFb -RI or -RII,
or TSP1 in rats with anti-Thy1 disease
To examine potential feedback mechanisms between
TSP1, active TGF-b , and TGF-b receptors in this model,
the amount of glomerular TSP1, TGF-b1 and -b2, as well
as TGF-bRI and -RII was evaluated, but no significant
changes could be detected comparing the different treat-
ment groups (Table 1, Fig. 2).
Blocking peptides does not affect mesangiolysis,
glomerular MC proliferation, or influx of macrophages
in rats with anti-Thy1 disease
Mesangiolysis. To ensure that disease induction was
equal in all groups, peptide treatment was started 16 hours
after anti-Thy1 antibody injection. In addition, mesan-
giolysis scores on day 3 were equal in all groups (not
shown).
MC proliferation. Because TGF-b has been shown to
inhibit MC proliferation in vitro [33], we also examined
if a reduced TGF-b activity in blocking peptide-treated
animals is accompanied by an increased proliferative re-
sponse of MC. As previously described [24, 28, 29, 34],
MC proliferation is already increased on day 3, peaks
on day 5, and ceases after day 7. Despite alteration of
TGF-b activity and matrix formation, the proliferative
response of the MC, as well as the total glomerular cell
count were unchanged by any peptide treatment in the
anti-Thy1 model (Fig. 5). This result was confirmed by
double staining of day 5 biopsies for MC and BrdU, indi-
cating the number of MC that have incorporated the in-
jected BrdU during the phase of DNA synthesis (OX-7+/
BrdU+ cells) (Fig. 5).
Influx of monocytes/macrophages. Since TGF-b
has been shown to be chemotactic for monocytes/
macrophages in vitro [35], the number of ED-1–positive
monocytes/macrophages per glomerular cross-section
was evaluated by immunostaining and did not differ in
any group during this experiment (Table 1).
Functional parameters: LSKL peptide infusion de-
creased proteinuria in experimental glomerulonephritis.
Proteinuria, a hallmark of severity of kidney disease, is
maximally increased around day 7 in the OX-7 antibody–
induced anti-Thy1 model (unpublished observation).
Either one of the blocking peptides reduced 24-hour pro-
teinuria on days 6 to 7 compared to control animals; while
the effect of the LSKL peptide was more dramatic and
did reach significant values, the reduced proteinuria in the
AAWSHW-treated rats did not reach significance due to
high standard deviation (Fig. 4F). Creatinine clearance
on day 7 as a measurement of kidney function tended
to be improved by infusion of either one of the block-
ing peptides, but did not reach significant values (SLLK
control 1.52 ± 0.2 mL/min, LSKL 1.78 ± 0.3 mL/min,
AAWSHW 1.87 ± 0.2 mL/min). Blood urea nitrogen was
also unchanged by the peptide treatment (SLLK control
33.2 ± 12.7 mg/mL, LSKL 33.2 ± 9.4 mg/mL, AAWSHW
23.6 ± 7.1 mg/mL). In addition, none of the blocking pep-
tides affected systolic blood pressure levels in diseased or
healthy rats (not shown).
DISCUSSION
Overproduction of TGF-b in response to injury
is thought to cause tissue fibrosis in many different
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Fig. 4. Blocking peptides decreased
glomerular extracellular matrix formation
and proteinuria in rats with anti-Thy1
disease. Treatment with blocking peptides
(LSKL, hatched bars; AAWSHW, black bars)
significantly reduced extracellular matrix for-
mation compared to control peptide (SLLK,
white bars), as evaluated by semiquantitative
scoring of Masson’s Trichrome staining (A),
or computerized image quantification of
immunostaining for collagen I (B), collagen
IV (C), and fibronectin (D) during the time
course of the anti-Thy1 model. Proteinuria
was detected in urine samples collected on
day 6/7 on a 24-hour period and demonstrated
a significant reduction in the LSKL (hatched
bars), but not AAWSHW (black bars) treated
versus the SLLK control group (white bars)
(E). The asterisk marks significant differences
(P < 0.01) of the blocking peptide groups
versus the control group.
inflammatory disease processes. This concept is particu-
larly well established in experimental glomerular disease
[4]. By most cells, TGF-b is secreted as a latent procy-
tokine complex that requires extracellular activation be-
fore it can interact with its receptors [15]. Despite great
interest in therapeutic anti-TGF-b strategies to treat fi-
brotic disease, the mechanism of TGF-b activation in any
inflammatory renal disease in vivo is still unknown. The
data presented above demonstrate that TSP1 is an im-
portant endogenous activator of TGF-b in inflammatory
kidney disease. Continuous systemic administration of
synthetic peptides inhibited glomerular TGF-b activa-
tion by TSP1 in rats with experimental mesangial pro-
liferative glomerulonephritis and provided a remarkable
reduction of glomerular extracellular matrix accumula-
tion and proteinuria, while MC proliferation or influx of
monocytes/macrophages was not affected.
In the anti-Thy1 model of mesangial proliferative
glomerulonephritis, a marked transient de novo expres-
sion of the matricellular protein TSP1 by MC (peak on
day 5) was regulated by FGF-2 and PDGF [24] and co-
incided with the up-regulation of TGF-b [5]. The data of
the current study demonstrate TSP1 as a major endoge-
nous activator of TGF-b in inflammatory kidney disease
and identify a potential therapy for disorders with over-
production (-activation) of TGF-b . Continuous systemic
infusion of a peptide (AAWSHW) that inhibits interac-
tion of TSP1 with the mature TGF-b protein (within the
TGF-b procytokine complex) [19] or infusion of a peptide
(LSKL) that blocks interaction of TSP1 with the LAP of
TGF-b was able to reduce the amount of active TGF-b
in glomeruli as assessed in three independent ways [20].
This inhibition of glomerular TGF-b activation was ac-
companied by a marked suppression of the glomerular
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Table 1. TGF-b receptor expression, glomerular TSP-1, and
glomerular macrophages are not affected by infusion of blocking
peptides in glomeruli after induction of the anti-Thy-1 model at days
3, 5, and 7
Treatment Day 3 Day 5 Day 7
Glomerular Control/SLLK 0.4 ± 0.3 2.0 ± 0.5 1.3 ± 0.9
TGF-bRI LSKL 0.2 ± 0.0 1.3 ± 03 0.9 ± 0.6
(Score 0–4) rv-amAAWSHWac 0.5 ± 0.5 1.4 ± 0.4 1.2 ± 0.5
Glomerular Control/SLLK 0.4 ± 0,2 1.9 ± 0.5 1.8 ± 1.0
TGF-bRII LSKL 0.2 ± 0.2 1.3 ± 0.3 1.9 ± 0.4
(Score 0–4) rv-amAAWSHWac 0.5 ± 0.4 1.9 ± 0.4 1.6 ± 0.6
Glomerular Control/SLLK 0.2 ± 0.2 1.9 ± 0.7 0.6 ± 0.3
TSP 1 LSKL 0.3 ± 0.2 1.2 ± 0.5 0.4 ± 0.3
(Score 0–4) rv-amAAWSHWac 0.7 ± 0.6 1.6 ± 0.7 0.8 ± 0.7
Glomerular control/SLLK 4.5 ± 1.5 1.9 ± 0.5 1.5 ± 0.4
macrophages
(ED-1+ cells/ LSKL 4.3 ± 1.9 1.0 ± 0.6 0.8 ± 0.5
glomerular
cross-section) rv-amAAWSHWac 3 ± 1.7 1.0 ± 0.5 0.7 ± 0.2
matrix excess. The LSKL peptide was slightly superior
in inhibiting activation of TGF-b and extracellular ma-
trix accumulation. In addition, the LSKL peptide treat-
ment also significantly reduced proteinuria, a hallmark of
severity of kidney disease, while the reduction of protein-
uria by the AAWSHW peptide did not reach significant
values. Both therapeutic effects of the peptide treatment,
suppression of extracellular matrix accumulation and
proteinuria, are in good agreement with previous studies
antagonizing TGF-b by antibodies, decorin injections, or
gene therapy [6–11].
Excessive proliferation of glomerular cells is charac-
teristic for many renal diseases and is frequently linked
to extracellular matrix accumulation [2]. Although TGF-
b inhibits cell proliferation in vitro in different cell types
including MC [33], the pathophysiologic role of TGF-b in
regard to mesangial cell proliferation in vivo is still con-
troversely discussed. In vivo transfection of the TGF-b1
gene into glomeruli of normal rats induced glomerular
hypercellularity [11], while transfer of the TGF-b1 gene
into nephritic glomeruli during anti-Thy1 disease [37] led
to a reduced glomerular mitogenic activity as determined
by 3H-thymidine incorporation. Other studies in the anti-
Thy1 model inhibiting TGF-b1 did not find any affect on
glomerular cell number [8], or did not evaluate glomeru-
lar cell proliferation [6, 7, 9]. Our study now demonstrates
that the TSP1-mediated activation of TGF-b is not influ-
encing MC proliferation in experimental mesangial pro-
liferative glomerulonephritis at any time point.
Influx of monocytes/macrophages into the glomerulus
is also a characteristic feature of inflammatory glomeru-
lar disease. While in vivo and in vitro studies have shown
that TGF-b1 can be chemotactic for mononuclear cells
as well as it can reduce macrophage adhesiveness poten-
tially leading to deactivation and/or increased clearence
from inflammatory sites [38], blocking peptide treatment
in this study did not affect glomerular macrophage accu-
mulation in the anti-Thy1 model.
Because TSP1 is able to activate both TGF-b1 and
TGF-b2 in an identical manner that can be blocked by
either peptide [20], and because glomerular TGF-b1 and
TGF-b2 are increased in the anti-Thy1 model ([39] and
this study), it cannot be excluded that the effect of the
blocking peptide treatment is caused by inactivation of
both TGF-b1 and TGF-b2. Nevertheless, the therapeutic
effect seen by TGF-b1 inhibition using polyclonal anti-
bodies or antisense oligonucleotides was very similar to
the effects of the blocking peptide treatment in this study
[6, 8].
Comparing the degree of glomerular TGF-b activation
and extracellular matrix formation in blocking peptide-
treated diseased animals to normal rats, our data suggest
that TSP1 is the major activator of TGF-b in this model.
The specific inhibition of TSP1-mediated TGF-b activa-
tion is consistent with the role of TSP1 in regard to TGF-b
activation during mouse postnatal development, and may
prove to be a great advantage as a potential anti-TGF-b
strategy in inflammatory disease as supported by studies
comparing the TSP1 and TGF-b1 null mice during mouse
development [21]. Pathologic changes in several organs
of the TSP1 null pups are caused by a reduced, but not
completely lacking activity of TGF-b , and the very se-
vere phenotype of the TGF-b1 null mice leading to early
death in a generalized excessive inflammatory response
[12] is not resembled by the TSP1 null mice [21]. In ad-
dition, mice with deletion of only one allele of TGF-b1
have generally reduced TGF-b1 serum and tissue levels,
which is associated with increased cell turnover and sus-
ceptibility to tumorigenesis in liver and lung [40], a find-
ing that has not been described for the TSP1 null mice.
Therefore, therapeutic strategies focusing on nonspecific,
systemic blockade of TGF-b ligand-receptor interactions
may have a problematic side effect profile considering
the complex function of TGF-b in vivo. In contrast, tar-
geting TSP1-mediated activation of TGF-b as a thera-
peutic intervention for fibrotic kidney disease may have
great promise because alternate activation pathways of
TGF-b for other functions are not affected. Specificity
of this treatment relates to the fact that TSP1-mediated
TGF-b activation requires a direct interaction of secreted
TSP1 and TGF-b in a complex extracellular neighbor-
hood, and that TSP1 is tightly regulated in disease. In
most in vitro systems or in normal tissues very little TGF-
b is present in its biologically active form. In contrast, the
latent TGF-b procytokine complexes and the TGF-b re-
ceptors are highly and widely expressed in most tissues.
In this context, it is interesting that in vivo gene transfer
of the constitutively active TGF-b1 gene into the lung of
rats caused extensive fibrosis, while overexpression of the
latent TGF-b1 transgene did not [41]. Although TGF-b
is also up-regulated in many disease processes including
the anti-Thy1 model, the studies described above and the
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data from this study suggest that regulation of TGF-b
activation and therefore, of a TGF-b activator, is criti-
cal to its profibrotic action. TSP1 perfectly fits into the
role of a tightly regulated activator of TGF-b that is in-
duced by other cytokines such as PDGF and FGF-2, as
well as potentially TGF-b in response to injury. While in
the normal rat glomerulus, glomerular TSP1 expression
is below detection level, in anti-Thy1 disease it is tran-
siently dramatically up-regulated by PDGF and FGF-2
[24] in parallel to TGF-b .
Because human renal diseases such as IgA nephropa-
thy usually progress over many years, continuous intra-
venous infusion of peptides is certainly not a therapeutic
option for slowly progressing human renal diseases. We
consider this study a “proof of principle study,” demon-
strating for the first time that blocking TSP1-TGF-b in-
teraction should be a future goal for developing drugs
(peptidomimetics) in renal disease. Structural studies are
ongoing to attempt to design such compounds. Although
the anti-Thy1 model cannot be directly compared with
human mesangial proliferative nephropathy, it is a renal
disease model mimicking many features of human renal
disease, and where renal matrix accumulation is clearly
shown to be TGF-b–dependent. In many injury models
in different organs as well as in human kidney disease [37,
43], TSP1 expression is consistent with a role of TSP1 in
mediating TGF-b activation and possibly fibrosis. There-
fore, while the pathogenetic role of this mechanism has to
be proven for each of these disease processes, this work
does define an important and novel molecular target that
may potentially apply to many different situations with
fibrosis.
CONCLUSION
The studies described above identify TSP1 as a major
activator of TGF-b in an inflammatory glomerulonephri-
tis model in the rat. This activator of TGF-b is tightly reg-
ulated by cytokines in response to injury in this model.
The interaction of TSP1 with TGF-b is responsible for
most of the glomerular matrix formation occurring in this
model, but does not appear to influence MC prolifera-
tion or macrophage accumulation. The link of TSP1 and
TGF-b in several experimental kidney disease models, as
well as the widespread up-regulation of TSP1 in exper-
imental inflammatory processes in other organs as well
as in human disease, suggests a central role of TSP1 in
mediating tissue fibrosis through interaction with latent
TGF-b . A therapeutic strategy inhibiting specifically only
the TSP1-mediated TGF-b activation in inflammatory
disease may prove to be especially favorable given the
known dual effects of TGF-b as a profibrotic as well as
an anti-inflammatory cytokine.
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